Discover a study that offers new insight into the link between frailty and steatotic liver disease in older adults.

GSK is set to acquire efimosfermin, a promising liver disease drug, from Boston Pharmaceuticals for a potential $2 billion.

London: GSK plc and Boston Pharmaceuticals, a clinical stage biopharmaceutical company developing highly targeted therapies ...

New research reveals that semaglutide significantly improves liver health in MASH patients. A new study published in the New ...

Under the agreement, GSK will acquire BP Asset IX, a subsidiary of Boston Pharmaceuticals, for up to $2 billion in total cash ...

British pharmaceutical giant GlaxoSmithKline announced Wednesday the acquisition of a drug under development to treat a ...

The prevalence of steatotic liver disease (SLD) was 33.3% in older adults, whereas fibrosis was less prevalent. Low physical activity, multimorbidity, and other factors were strongly associated ...

Steatotic liver disease (SLD), including metabolic dysfunction-associated steatohepatitis (MASH) and metabolic dysfunction-associated steatotic liver disease (MASLD), is one of the most common forms ...

GSK will gain access to efimosfermin by acquiring Boston’s subsidiary BP Asset IX for $1.2bn upfront and up to $800m in ...

With its purchase of Boston Pharmaceuticals' drug, GSK extends a streak of dealmaking it's undertaken to build a liver ...

GSK will acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa, a phase III-ready investigational specialty medicine.

GSK announced on Wednesday that it has entered into an agreement with Boston Pharmaceuticals to acquire its lead asset ...